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Astragali radix: could it be an 
adjuvant for oxaliplatin-induced 
neuropathy?
Lorenzo Di Cesare Mannelli1, Alessandra Pacini2, Laura Micheli1, Angelo Pietro Femia1, 
Mario Maresca1, Matteo Zanardelli1, Alfredo Vannacci1, Eugenia Gallo1, Anna Rita Bilia3, 
Giovanna Caderni1, Fabio Firenzuoli1, Alessandro Mugelli1 & Carla Ghelardini1
Neurotoxicity is a major side effect of platinum derivatives both during and after treatment. In the 
absence of effective pharmacological compounds, the opportunity to identify safe adjuvant treatments 
among medicinal plants seems appropriate. Astragali radix is an adaptogenic herbal product recently 
analyzed in platinum-treated cancer patients. With the aim of evaluating the anti-neuropathic profile of 
Astragali radix, a previously characterized aqueous (Aqu) and two hydroalcoholic (20%HA and 50%HA) 
extracts were tested in a rat model of oxaliplatin-induced neuropathy. Repeated administrations 
significantly reduced oxaliplatin-dependent hypersensitivity with 50%HA, the most effective, fully 
preventing mechanical and thermal hypersensitivity. Ex vivo, 50%HA reduced morphometric and 
molecular alterations induced by oxaliplatin in peripheral nerve and dorsal-root-ganglia. In the 
spinal cord and in brain areas, 50%HA significantly decreased activation of microglia and astrocytes. 
Furthermore, 50%HA prevented the nephro- and hepato-toxicity induced by the anticancer drug. The 
protective effect of 50%HA did not alter oxaliplatin-induced apoptosis in colon tumors of Pirc rats, 
an Apc-driven model of colon carcinogenesis. The hydroalcoholic extract (50%HA) of Astragali radix 
relieves pain and promotes the rescue mechanisms that protect nervous tissue from the damages 
triggering chronic pain. A safe profile strongly suggests the usefulness of this natural product in 
oxaliplatin-induced neuropathy.
Oxaliplatin is a third-generation platinum drug, extensively used, in a combination with 5-fluorouracil and leuco-
vorin, for the management of locally advanced and metastatic cancer of the colon or rectum1. A major limitation 
associated with the use of oxaliplatin is represented by its neurotoxicity, which leads to painful neuropathy. Acute 
symptoms appear shortly after infusion but usually vanish within a week2. By contrast, cumulative oxaliplatin admin-
istrations cause chronic neuropathy in approximately 50% of patients receiving doses higher than 1000 mg/m2 3,4. 
Paresthesia, dysesthesia and pain combined with a glove-and-stocking distribution sensory loss are the most 
common signs of neuropathy development5,6. During treatment, chemotherapy-induced neuropathy can limit 
therapeutic options for patients and result in dose reduction. During survival, it might greatly affect the patient’s 
quality of life7.
The 2014 practical clinical guideline from the American Society of Clinical Oncology states that there are 
no agents recommended for the prevention of chemotherapy-induced neuropathic pain8. No progress has 
been achieved up to now9. High-quality, consistent evidence is insufficient; the best available data support a 
moderate recommendation for treatment with duloxetine10,11. Consequently, the prevention or treatment of 
oxaliplatin-induced neuropathy (as well as other chemotherapy induced neuropathies) is a relevant therapeutic 
need.
In this context, a scientific approach to the study of medicinal plants may help to identify adjuvant treatments 
able to reduce the side effects of chemotherapy. Phytotherapy is based on the combined action of a mixture 
of constituents able to offer a multiple approach to the multi-factorial nature of neuropathy pathogenesis. The 
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bioactivity of crude drugs or vegetal extracts is a summation of antagonistic and/or synergistic effects on bioavail-
ability, cellular transport processes, compound metabolism and pharmacodynamic mechanisms12.
Recently, we demonstrated the protective effect of different extracts of Astragali radix in a cellular model of 
oxaliplatin-induced neurotoxicity13. Importantly, none of the tested extracts interfered with the toxicity elicited 
by oxaliplatin in the human colon adenocarcinoma cell line HT-29.
Astragali radix is one of the important “Qi tonifying” or adaptogenic herbs from the Chinese materia medica 
(recently introduced in the European Pharmacopoeia). It has been prescribed for centuries for general debility, 
chronic illnesses, and to increase the overall vitality of the system14. Current evidence about the combination of 
Astragalus extracts and chemotherapy (in particular with the FOLFOX regimen) highlight a significant improve-
ment in the patient’s quality of life15–18.
The present study is focused on the evaluation of the anti-neuropathic properties of different Astragali radix 
extracts (aqueous, Aqu, and two hydroalcoholics, 20%HA and 50%HA) in rats subchronically treated with oxalip-
latin. The relief of pain hypersensitivity as well as the protective effects on the peripheral and central nervous sys-
tem were analyzed. Finally, the influence of Astragalus on the anticancer properties of oxaliplatin was evaluated in 
Pirc rats, an Apc-driven model of colon carcinogenesis, measuring oxaliplatin-induced apoptosis in colon tumors 
as a marker of its therapeutic effect.
Results
Behavioral measurements. On day 21, oxaliplatin administration to Sprague-Dawley rats (2.4 mg kg−1 
intraperitoneally - i.p. - daily, for 5 consecutive days/week for 3 weeks) altered the sensitivity to both noxious 
and non-noxious mechanical stimuli. As measured by the Paw pressure test, oxaliplatin treatment lowered the 
pain threshold in response to a mechanical noxious stimulus, reducing the control value from 66.5 ± 1.9 g to 
40.7 ± 1.8 g (Fig. 1A). The treatment with Aqu and 20%HA (300 mg kg−1 per os - p.o. - daily from the first day 
in which the chemotherapic compound was injected) reduced the pain behavioral alterations whereas 50%HA 
(300 mg kg−1 daily p.o. following the same protocol) fully prevented the sensitivity to noxious mechanical stimuli 
(Fig. 1A).
The withdrawal threshold to a non-noxious mechanical stimulus, measured by the electronic Von Frey 
apparatus, was decreased in oxaliplatin-treated animals (day 21) from 23.7 ± 1.2 g, to 13.8 ± 0.9 g (Fig. 1B). The 
pro-allodynic effect of oxaliplatin was significantly reduced by Aqu and totally prevented by both 20%HA and 
50%HA (Fig. 1B).
The response to a non-noxious thermal stimulus is shown in panel C of Fig. 1. The anticancer agent decreased 
the licking latency in the Cold plate test from 24.1 ± 1.2 s (vehicle + vehicle) to 16.2 ± 0.8 s (oxaliplatin + vehicle). 
Administration of 50%HA was the only dose able to significantly reduce oxaliplatin-induced cold hypersensitivity 
(Fig. 1C).
The above described treatments with Aqu, 20%HA and 50%HA performed on control rats (which did not 
receive oxaliplatin) did not alter the pain threshold evaluated using the Paw pressure, Von Frey and Cold plate 
tests (Fig. 1A,B and C).
To better evaluate the pain relief profile of 50%HA, the extract was administered p.o. daily (subchronic; from 
the first day in which oxaliplatin was injected) at 3 different dosages, 30, 100 and 300 mg kg−1. On day 21, the pain 
threshold measurement by the Paw pressure test showed that 50%HA provided a dose-dependent protective effect 
after repeated treatment (Fig. 2, subchronic). The full efficacy of 50%HA was shown also on day 14, suggesting 
early beneficial effects (Supplementary Fig. S1). On the contrary, 300 mg kg−1 50%HA acutely administered p.o. 
on day 21 did not modify the pain threshold decreased by oxaliplatin (Fig. 2, acute).
Once evaluated the activity of the phytocomplex 50%HA, we aimed to enquire the possible efficacy of sin-
gle fractions of the crude extract. 50%HA was suspended in water and extracted with solvents with increasing 
polarity (dichloromethane, ethyl acetate, butanol, water). After liophylization we obtained solid products in the 
following percentage (compared to the quantity of the total extract): 1) dichloromethane fraction, 22%; 2) ethyl 
acetate fraction, 3%; 3) butanol fraction, 6%; 4) water fraction, 69%. Accordingly, different groups of animals 
were treated with dosages representing these percentages of the total extract dose (300 mg kg−1). In particular, 
1) dichloromethane fraction, 66 mg kg−1; 2) ethyl acetate fraction, 9 mg kg−1; 3) butanol fraction, 18 mg kg−1; 4) 
water fraction, 207 mg kg−1. These treatments were compared with effects due to the administration of the mix-
ture of all fractions at the same doses. As shown in the Supplementary Fig. S2, none of the single fractions induced 
a significant effect whereas the animals that received the co-administration of all the fractions showed a decrease 
of pain hypersensitivity comparable to that induced by the total crude extract.
Finally, oxaliplatin negatively influenced motor coordination. The Rota rod test measures the walking time 
and number of falls in 600 s from a rotating rod. Oxaliplatin-treated animals showed reduced walking time 
(197.8 ± 24.8 s; Supplementary Fig. S3A) and an increased number of falls (4.4 ± 0.5; Supplementary Fig. S3B) 
in comparison with control animals (600 s and 0.7 ± 0.3, respectively). Repeated administration of each 
Astragali radix extract (300 mg kg−1 daily p.o. starting from the first day of oxaliplatin injection) restored 
motor coordination, improved the time spent in equilibrium on the rod and reduced the number of falls 
(Supplementary Fig. S3B). In the absence of oxaliplatin, repeated treatment with Astragalus extracts did not alter 
motor coordination per se (Supplementary Fig. S3A and B).
p-NF-H expression in the sciatic nerve. Expression level evaluation of the phosphorylated form of the 
heavy polypeptide of neurofilament (p-NF-H, a major determinant of axonal structure and functionality19) in the 
rat sciatic nerves showed an oxaliplatin-dependent down-regulation (Fig. 3A, oxaliplatin + vehicle) compared 
to the vehicle control group (Fig. 3A, vehicle + vehicle). Compared to the oxaliplatin group, nerve sections of 
50%HA treated rats (Fig. 3A, vehicle + 50%HA) exhibited a p-NF-H increment. The immunolabeling observed in 
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the presence of 50%HA alone (Fig. 3A, vehicle + 50%HA) did not show any significant difference in comparison 
to control (Fig. 3A, vehicle + vehicle).
Histology and morphometry of dorsal root ganglia (DRG). The features of oxaliplatin-induced neu-
ronopathy have already been reported in detail19–21. To summarize, the main pathological changes were found 
in the nucleolus and the nucleus of the DRG neuronal cells where an increased incidence of multinucleolated 
cells (Fig. 3B, black arrow in oxaliplatin + vehicle, and striped bar in upper histogram) and nucleolar segregation 
(Fig. 3B, black arrow in oxaliplatin + 50%HA, and striped bar in lower histogram) were evidenced. On the con-
trary, the neuronal cytoplasmic involvement was very limited. Quantitative analysis of the multinucleated nuclei 
(upper histogram) and eccentric nucleoli (lower histogram) in the presence of 50%HA was significantly reduced 
(Fig. 3B, oxaliplatin + 50%HA and gray bars) compared to oxaliplatin alone.
ATF-3 expression in L4-L5 DRG. Expression of the activating transcription factor 3 (ATF-3) in DRG is 
considered a neuronal marker of nerve injury22. Immunohistochemistry was used to assess its expression in the 
presence or in the absence of 50%HA (Fig. 3C). ATF-3-positive cells from 3 non-adjacent transverse sections 
(10 μ m) of L4 and L5 DRG per animal (n = 6 per group) were counted, and expressed as a percentage of the 
total number of cells counted in these sections. DRG neurons showed significant ATF-3 expression following 
oxaliplatin treatment (striped bar), whereas the presence of 50%HA (gray bar) displayed a significant reduction 
of ATF-3 nuclear immunoreactivity. No differences were observed following 50%HA treatment alone (white bar) 
Figure 1. Behavioral measurements. (A) and (B) Pain: mechanical noxious and non-noxious stimuli.  
(A) Paw pressure test was used to measure sensitivity to a mechanical noxious stimulus. (B) The Von Frey test 
was used to measure the pain threshold as a response evoked by a non-noxious stimulus. (C) Pain: thermal 
non-noxious stimuli. The Cold plate test was used to evaluate the pain threshold measuring the latency to pain-
related behavior (lifting or licking of the paw). Oxaliplatin (2.4 mg kg−1) was administered daily i.p. for 3 weeks. 
All Astragalus extracts (300 mg kg−1) were administered daily p.o. concomitantly with oxaliplatin. Behavioural 
evaluations were performed on day 21, 24 h after the last injection. Control animals were treated with vehicles. 
Each value represents the mean of 12 rats per group, performed in two different experimental sets. Values are 
represented as mean ± SEM. *P < 0.01 versus saline treatment; ^P < 0.05 and ^^P < 0.01 versus oxaliplatin 
treatment.
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in comparison with control (black bar). Representative photomicrographs show the 50%HA protective nuclear 
effect (oxaliplatin + 50%HA) compared to oxaliplatin treatment (oxaliplatin + vehicle, black arrows).
Spinal and cerebral glial analysis. As we have previously reported19, a 3 week oxaliplatin treatment is 
associated with a numeric and morphological astrocyte boost within the spinal cord, where the increase in the cell 
body size denotes their typical activated state (Fig. 4A, oxaliplatin + vehicle, see insert for morphological details). 
On the contrary, microglia did not undergo any of the above modifications (data not shown). Treatment with 
50%HA resulted in a numerical reduction of astrocytes within the dorsal horns as demonstrated by immuno-
histochemistry for the astrocytic marker Glial Fibrillary Acidic Protein (GFAP) (Fig. 4A, oxaliplatin + 50%HA). 
Rats that received only 50%HA (vehicle + 50%HA) were indistinguishable from control rats (vehicle + vehicle), 
showing no astrogliosis or morphological modifications.
Under the same conditions, we measured the density of astrocytes (GFAP) and microglia (by means of the 
Iba1 specific marker) in several brain areas known to be active during chronic pain23,24 and already demon-
strated to be involved in cerebral gliosis following oxaliplatin-administration19. In all examined areas, our results 
demonstrated a 50%HA-dependent reduction in the density of both astrocytes and microglia (Fig. 4B and C, gray 
bars, respectively) in comparison to oxaliplatin-treated rats (striped bars). Rats treated with only 50%HA did not 
exhibit any differences from control animals (data not shown).
Nrf2 and NQO1mRNA levels in the nervous system. To assess the redox profile after treat-
ments, two major cellular antioxidant players were analyzed. Oxaliplatin treatment did not modify the 
nuclear factor (erythroid-derived 2)-like 2 (Nrf2) mRNA either in the sciatic nerve or in the spinal cord 
(Supplementary Fig. S4A and C). On the contrary, Nrf2 increased in DRGs, 50%HA significantly prevented this 
alteration (Supplementary Fig. S4B). 50%HA decreased Nrf2 spinal levels (oxaliplatin + 50%HA) in compari-
son to control (Supplementary Fig. S4C). Similarly, 50%HA decreased the NAD(P)H dehydrogenase, quinone 1 
(NQO1) (oxaliplatin + 50%HA) in DRGs in comparison to control (Supplementary Fig. S4B). Oxaliplatin 
reduced NQO1 levels in the spinal cord, 50%HA was not effective (Supplementary Fig. S4C).
Hepatic and renal histopathological features. Given the neuroprotective properties of 50%HA, we 
examined its potential protective effects against hepatic and renal toxicity induced by oxaliplatin treatment. The 
macroscopic liver appearance of the vehicle + vehicle-treated animals appeared normal without any alterations in 
terms of shape, dimension, hue or solidity (data not shown). The microscopic examination of liver sections from 
the control rats showed a normal lobular pattern, hepatic cells with well-preserved cytoplasm, prominent nucleus, 
nucleolus and a well-defined central vein. There was no sign of inflammation or fatty change (Fig. 5A, vehi-
cle + vehicle). In animals administered with oxaliplatin alone, liver sections showed marked congested central 
veins and sinusoids, multifocal areas of necrosis, increased fatty deposits (insert in Fig. 5A, oxaliplatin + vehicle, 
black arrow) and the presence of inflammatory cells with granular swelling (insert in Fig. 5A, oxaliplatin + vehi-
cle, black arrowhead). Treatment with 50%HA resulted in a considerable reduction in necrotic areas, with disap-
pearance of inflammatory infiltrates and a remarkable improvement in the macrovesicular fatty changes of the 
hepatic parenchyma (Fig. 5A, oxaliplatin + 50%HA). Figure 5A (vehicle + 50%HA) shows that there was no sign 
of alterations in animals administered with 50%HA alone.
Figure 2. Behavioral measurements. Pain: subchronic and acute effect of 50%HA. On day 21, the pain reliever 
effect of 50%HA was evaluated by Paw pressure test. Oxaliplatin (2.4 mg kg−1) was injected daily i.p. for 3 weeks. 
(A) Increasing dosages (30, 100, 300 mg kg−1) of 50%HA were administered daily p.o., behavioural evaluations 
were performed 24 h after the last injection; (B) The acute effect of a single 50%HA administration (300 mg kg−1 
p.o.) was evaluated 30 min after administration. Control animals were treated with vehicles. Each value 
represents the mean of 12 rats per group, performed in two different experimental sets. Values are represented as 
mean ± SEM. *P < 0.01 versus saline treatment; ^P < 0.05 and ^^P < 0.01 versus oxaliplatin treatment.
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Figure 3. Effect of 50%HA on oxaliplatin-dependent damages of the peripheral nervous system. The protective 
effect of 50%HA was evaluated on the sciatic nerve and in DRGs of treated animals on day 21. (A) p-NF-H expression 
levels in sciatic nerve. A representative immunohistochemical staining for p-NF-H in 10 μ m longitudinal sciatic nerve 
sections is shown. For all images the scale bar = 10 μ m and the original magnification was 20X. Bars show quantitative 
evaluation of neurofilament expression levels obtained by densitometric analysis. (B) Morphological aspects of DRG 
nuclei and nucleoli. The protective effect of repeated administrations of 50%HA was evaluated on oxaliplatin-damaged 
DRGs on day 21. Five μ m DRG sections were stained by the Azan-Mallory method. Light micrographs (for all images: 
scale bar = 5 μ m, original magnification 40X) were analyzed by measuring the occurrence of eccentric nucleoli (black 
arrowhead) and multinucleolated neurons (black arrow). Histograms show the incidence of nuclear and nucleolar 
pathological features in the absence (black bars) and in the presence of 50%HA (grey bars). (C) ATF-3 expression 
in L4-L5 DRGs. Typical immunohistochemistry images of ATF-3 expression in the DRG following oxaliplatin 
(oxaliplatin + vehicle) and oxaliplatin combined with 50%HA (oxaliplatin + 50%HA) treatments (day 21). ATF-3 
staining is clearly punctuate and confined to the nucleus, shown as intense compact staining in brown (black arrows). 
The percentage of ATF-3-positive neurons in L4 and L5 DRGs is shown in the histogram. All images: scale bar = 10 μ 
m, original magnification 20X. Each value represents the mean ± SEM of 6 rats per group, performed in two different 
experimental sets. *P < 0.05 versus vehicle + vehicle; ^ P < 0.05 and ^ ^P < 0.01 versus oxaliplatin + vehicle.
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Figure 5B (oxaliplatin + vehicle) shows representative hematoxylin-eosin stained sections demonstrating the 
glomerulopathy with cytopathic changes developed by oxaliplatin-treated kidney. In particular, glomerular alter-
ations consisted of mesangial expansion (Fig. 5B left panel, oxaliplatin + vehicle, black arrowhead), glomerular 
hyalinization, Bowman’s space expansion (Fig. 5B left panel, oxaliplatin + vehicle, black asterisk) with a coarcta-
tion of the entire glomerulus, and Bowman’s capsule basement membrane thickening (Fig. 5B left panel, oxalip-
latin + vehicle, black arrow). The administration of 50%HA concurrently with oxaliplatin, exhibited protective 
effects detectable as less severe glomerular damages and a reversal of the vacuolar degenerative changes of the 
tubular cells (Fig. 5B, oxaliplatin + 50%HA).
Figure 4. Effect of 50%HA on oxaliplatin-dependent astrogliosis in the central nervous system (A) Spinal 
cord. On day 21, the number of GFAP-positive cells was measured in the dorsal horn of the spinal cord. 
Representative immunohistochemical staining is shown (scale bar = 10 μ m and original magnification 20X, 
for all images) and black arrows evidenced that the activate astrocytic morphology induced by oxaliplatin 
administration (oxaliplatin + vehicle) is completely reverted by 50%HA presence. (B) and (C) Brain areas. The 
number of (B) GFAP- and (C) Iba-1-positive cells was evaluated in oxaliplatin-treated rats on day 21 analyzing 
the following areas: Cg1, cyngulate cortex area 1; S1, primary somatosensory cortex; M1, primary motor cortex; 
PAG, periaqueductal grey; mfb, medial forebrain bundle. Each value represents the mean ± SEM of 6 rats 
per group, performed in two different experimental sets. *P < 0.05 versus vehicle + vehicle; ^P < 0.05 versus 
oxaliplatin + vehicle.
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Figure 5. Histological evaluation of liver and kidney. (A) Effect of 50%HA on counteracting histopathological 
damages induced by oxaliplatin in the liver of rats. In the control animals (vehicle + vehicle), no liver damage was 
observed. Following oxaliplatin treatment (oxaliplatin + vehicle), fatty change (insert in oxaliplatin + vehicle, black 
arrows) and inflammatory cell with granular swelling were observed. The liver sections from oxaliplatin + 50%HA 
show little balloon changes in liver acinus, whereas 50%HA treated animals (vehicle + 50%HA) show no 
differences with control rats. Scale bar = 10 μ m and original magnifications 20X for all the panels.  
(B) Effect of 50%HA on counteracting histopathological damages induced by oxaliplatin in the kidney of rats. 
The control animals (vehicle + vehicle) show any signs of kidney damage. Following oxaliplatin treatment 
(oxaliplatin + vehicle), kidney sections show glomerulopathy with Bowman’s space expansion (left panel, black 
asterisk), Bowman’s capsule thickening (left panel, black arrow), and mesangial expansion (left panel, black 
arrowhead), and tubule epithelium swelling and distension, together with severe vacuolar degeneration (right 
panel, black arrow). Oxaliplatin + 50%HA kidney section shows no pathological changes, as well as the kidney 
section from 50%HA-treated animals (vehicle + 50%HA). Scale bar = 10 μ m and original magnifications 40X for 
all panels. All pathological observations were performed and graded by experienced and independent pathologists 
on 6 rats per group (two different experimental sets).
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Apoptosis in tumors and normal mucosa of Pirc rats. To gather information on the possible inter-
ference of Astragalus with the toxic effect of oxaliplatin in colon tumors, we measured the level of apoptosis in 
tumors and normal mucosa of Pirc rats with spontaneous tumorigenesis. Oxaliplatin or oxaliplatin + 50%HA 
was administered to Pirc rats from the eighth to the ninth months of age, when colon tumors had already devel-
oped. These animals were more sensitive to the general toxicity of oxaliplatin, showing strong anemia, asthenia 
and weight loss when treated with 2.4 mg kg−1 oxaliplatin daily. For this reason, the treatment was modified to 
1.5 mg kg−1 i.p. twice weekly for 4 weeks. As shown in Fig. 6A, Pirc rats showed hypersensitivity to mechanical 
stimuli (Paw pressure test) starting on week 1 (after two injections) with a continual pain threshold decrease over 
time.
In parallel, another group of animals underwent a 4-week treatment with oxaliplatin (1.5 mg kg−1 i.p. twice 
weekly) and 50%HA (300 mg kg−1 p.o. daily starting on the first day of oxaliplatin administration). 50%HA sig-
nificantly prevented pain development (Fig. 6A). The week 4 was chosen as optimal for neuropathy establish-
ment and duration of 50%HA treatment. On week 4, Pirc rats (9 months old) were sacrificed and apoptosis was 
evaluated in colon tumors as well as in the apparently normal mucosa. The treatment with 50%HA did not affect 
the apoptotic index either in the normal mucosa or in the tumors (Fig. 6B), demonstrating that 50%HA did not 
interfere with oxaliplatin’s pharmacological effect. In agreement with other authors25, the level of apoptosis in 
tumors was significantly higher than that in normal mucosa.
Discussion
The present data show the anti-neuropathic effects of different Astragali radix extracts in a rat model of 
oxaliplatin-induced neurotoxicity. In particular, 50%HA controls pain and prevents damage to the peripheral 
nervous system and the maladaptive changes along the entire nociceptive pathway within the central nervous 
system.
Aqu, 20%HA, and 50%HA significantly reduce the pain sensitivity alterations caused by repeated administra-
tions of the platinum derivative. 50%HA is the most effective, fully preventing hypersensitivity to suprathreshold 
stimulation (hyperalgesia-related measurement) and pain threshold alterations to stimuli that normally do not 
provoke pain (allodynia-related measurement). Pain relief was observed after a subchronic treatment, suggesting 
a neuroprotective mechanism against the damages that result in chronic pain. Accordingly, 50%HA prevents 
Figure 6. Pirc rats. (A) Pain threshold evaluation by Paw pressure test. Rats were treated with oxaliplatin 
1.5 mg kg−1 i.p. twice a week for 4 weeks. 50%HA (300 mg kg−1) was administered p.o. daily for 4 weeks. 
Behavioural evaluations were performed 24 h after the last injection of both compounds. (B) Apoptotic 
index (number of apoptotic cells/cells scored x 100) in the normal mucosa (NM) and tumours from Pirc rats 
treated with oxaliplatin (oxaliplatin + vehicle) or oxaliplatin + 50%HA as explained in methods. Values are 
mean + SEM (n = 5, and 4 for NM and 9 and 13 for tumours in oxaliplatin + vehicle, and oxaliplatin + 50%HA, 
respectively). Bars with different superscript are significantly different (P < 0.01 with t-test).
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morphological derangements in DRGs, a primary target for oxaliplatin neurotoxicity19,26, as well as the signif-
icant increase in ATF-3 expression, a member of the ATF-3/cAMP-responsive element binding protein family 
considered a selective marker of neuronal damage19,20,27. Moreover, 50%HA prevents the downregulation of the 
phosphorylated heavy neurofilament, a parameter indicative of latent axonal damage19,28.
In vitro, we recently described the protective characteristics of 50%HA against the toxicity evoked by oxalip-
latin in primary astrocytes13. Glial cells have been recognized as powerful modulators of pain29. The metabolic 
activation of microglia and astrocytes participates in the maladaptive plasticity of the central nervous system, 
facilitating nociceptive processes, generating clinical pain hypersensitivity and making neuropathic pain an 
autonomous disease state29.
Despite the limited ability of oxaliplatin to cross the blood brain barrier30, we previously observed glial acti-
vation induced by oxaliplatin in spinal cord and brain areas differently according to cell type, anatomical region, 
and treatment time-points19. The increased cell density of microglia and astrocytes is strongly related to pain 
hypersensitivity since the glial inhibitor minocycline and fluorocytrate fully prevent oxaliplatin-evoked pain21. 
The present results reveal an inhibitory effect of 50%HA on microglia and astrocytes (decreasing in the number 
of both cell types) in the dorsal horn of the spinal cord, in brain areas belonging to the “pain neuromatrix”31 and 
in other brain networks involved in somatosensory, motor, attention and emotional processing32. To note, 50%HA 
seems to be able to modulate glial cells instead of acting as a general depressor of glial functions. The homeostatic 
properties of the Astragalus extract may allow inhibition of glial hyper-reactivity but preserve neuroprotection, a 
housekeeping role of these cells33.
Several bioactive compounds have been highlighted in the dried root of Astragalus such as isoflavonoids (cal-
ycosin and formononetin), triterpene saponins (whose major component is represented by Astragaloside IV)34, 
polysaccharides, amino butyric acids and various trace elements15,35,36. The phytochemical characterization of 
the present extracts reveals the presence of these active compounds, showing similar contents of total sapon-
ins in Aqu, 20%HA and 50%HA whereas isoflavones are more concentrated in the hydroalcoholic extracts of 
Astragali radix rather than in Aqu13. Since Astragalus flavonoids, saponins and polysaccharides15,36,37 possess 
considerable activities against oxidative imbalance and oxaliplatin induces oxidative damage relevant for pain 
sensitivity38, the mRNA levels of redox-related molecules are studied in different nervous districts. Nrf2 is an 
important cellular defense response against oxidative or electrophilic stress39, it plays an imperative role in inhib-
iting oxidative stress via upregulating the Nrf2-driven antioxidants, including mainly heme oxygenase 1 (HO-1), 
NQO1 and γ -glutamate-cysteine ligase (γ -GCL)40. In oxaliplatin-treated animals Nrf2 slightly increases in DRGs 
whereas NQO1 decreases in the spinal cord. 50%HA reduces both Nrf2 and NQO1 levels in DRGs and spinal 
cord, suggesting the lack of a direct stimulation of the cellular antioxidant machinery. Nevertheless, because of the 
neuroprotective profile of 50%HA, less need of physiological antioxidant responses after Astragalus administra-
tion could be hypothesized. The neuroprotective properties of Astragalus root components have been previously 
described. Formononetin was able to preserve neurons from apoptosis41. Astragaloside IV reduced caspase-3 
activation, protected fiber demyelination and promoted peripheral nerve regeneration in animal models of 
neuropathy42.
A general restorative property of Astragalus extracts has also been reported: anti-hypertensive and immuno-
modulatory activities15 as well as the capability to protect the liver and reduce hyperglycemia43. In the present 
results, histological observations of the liver and kidney also strongly support the hepato- and kidney-protective 
effect of 50%HA against oxaliplatin-induced organ toxicity.
It is relevant to underline that the efficacy of 50%HA is strongly related to the whole phytocomplex. Aimed 
to study the role of the different chemical families present in the extract, we have been performed a fractionation 
by solvents with increasing polarity (dichloromethane, ethyl acetate, butanol and water). The procedure let to the 
separation of constituents on the basis of their different polarity, namely lipophilic constituents have been solu-
bilized in dichloromethane, the aglycons of saponins and flavonoids and their less polar glycosides in ethyl ace-
tate, saponins and flavonoids glycosides (and all the other polar constituents not completely soluble in water) in 
butanol. Final water fraction contains only constituents such as simple sugars or polysaccharides. After repeated 
administrations, none of these fractions show pain relieving properties in oxaliplatin-treated animals. On the 
contrary, the animals that received the co-administration of all the fractions show a decrease of pain hypersen-
sitivity comparable to that induced by the total crude extract suggesting the synergy of several compounds and 
validating the traditional phytotherapic approach.
As regards safety against chemotherapy, the lack of interference of Astragalus extract (50%HA) in 
oxaliplatin-induced caspase-3 activation and cell mortality in the colon cancer cell line HT-29 has been previ-
ously reported13. In the present study, the possible Astragalus interference with the anticancer activity of oxalip-
latin was evaluated in vivo in Pirc rats, a genetic model of colon cancer. This rat strain harbors a heterozygous 
mutation in Apc, the key gene in colon carcinogenesis. Accordingly, Pirc rats spontaneously develop tumors in 
both the small and large intestines, mimicking the human pathology44. We used this model to ascertain if 50%HA 
would impede the chemotherapic effect of oxaliplatin on tumors. Apoptosis was measured in the normal mucosa 
and tumors, and our results indicate that 50%HA does not interfere with oxaliplatin-induced apoptosis in either 
tissue, thus suggesting that Astragalus does not modify the anticancer efficacy of the platinum derivative.
On the other hand, compelling evidence suggests the usefulness of Astragali radix in cancer treatment. 
Astragalus is included among the specific plants that contribute to tumor response when combined with 
oxaliplatin-based chemotherapy for colorectal cancer17. The combination of Chinese herbal medicine, including 
Astragali radix, improved the effectiveness of FOLFOX against advanced colon cancer in terms of tumor response 
rate and one-year survival. Patients also reported fewer adverse effects and experienced better quality of life16. A 
metanalysis of randomized trials concluded that Astragalus-based treatment increased the efficacy (by improving 
survival, tumor response, and performance status) and reduced the toxicity of standard platinum-based treat-
ment in patients affected by advanced non–small-cell lung cancer45. Anticancer properties were suggested for 
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Astragaloside IV which exhibited in vivo anticancer activity and enhanced immune response46. Astragalus sapo-
nins inhibited proliferation in a human colorectal cancer HT-29 cell line regardless of the p53 status, demonstrat-
ing tumor suppressive effects in a nude mice xenograft model and enhancing the cytotoxic effect of 5-FU47. Cui 
et al. highlighted the anti-tumoral activity of Astragalus membranaceus in counteracting hepatocarcinogenesis in 
rats48. Astragalus polysaccharides have demonstrated to have anti-proliferative effects in cell-line studies49.
Conclusions
Since improved cancer therapy has led to increased life expectancy and cure rates in most types of cancers, the 
issue of symptom management has begun to play a very important role6. Pain is a prominent under-treated 
symptom in cancer50; no effective agents are available for the treatment of chemotherapy-induced neuropathy8. 
The Astragali radix hydroalcoholic extract 50%HA was able to control oxaliplatin-induced pain and prevent alter-
ations in both the peripheral and central nervous system. 50%HA may offer a dual protective approach against 
etiological factors and resulting maladaptive plasticity without altering the anticancer efficacy of oxaliplatin.
Methods
Plant material, sample preparation and analysis. A commercial sample (0.5 kg dry herbal drug) of 
Astragali radix (Huang Qi) was purchased from Gansu China Shenzhen Green Nature Co. LTD. The Art. No. 
was 30 237, China production lot no. 0061, July 2010. The plant material was comminuted, reduced to a powder 
form, and used to make the extracts. The decoction (Aqu) was prepared using 5 g of the herbal drug plus 100 mL 
distilled water and boiled for 4 h on a heating plate (adding water when necessary to maintain a constant volume). 
After 4 h of boiling, the decoction was cooled down to room temperature on a horizontal shaker to improve the 
bottom deposition of the solid drug. It was then filtered and centrifuged (5000 rpm, Δ t = 10 min, temp. = 20 °C), 
and after that, the extract was frozen (− 24 °C) and lyophilized.
The 20%HA extract was prepared with 5 g of the herbal drug plus 25 mL of EtOH 80%. The mixture was left 
under horizontal shaking at room temperature (25 °C) for 2 days, filtered, and extracted twice. Solutions were 
combined, concentrated under low pressure to eliminate EtOH, frozen (− 24 °C), and lyophilized.
The 50% hydroalcoholic dried extract (50%HA) Axtragyl™ was purchased from Giellepi S. p. A. Health Science 
Division. The extract was reported to contain 30% maltodextrins as eccipients.
For the quantitative HPLC analysis, the following standards were used: Astragaloside IV, European 
Pharmacopoeia (EP) reference standard (97.8%) and formononetin ( ≥99% by HPLC) from Sigma-Aldrich. 
Dextrans with increasing and defined molecular weights (5000, 150 000, 270 000, 670 000 Da) were from 
Sigma-Aldrich. The full characterization of the Astragalus extracts has been previously published13.
Subsequently, 50%HA was fractioned using solvents with increasing polarity. The crude extract was suspended 
in water and extracted with 1) dichloromethane, 2) ethyl acetate and 3) butanol. Dried extracts were obtained by 
evaporation of dichloromethane, ethyl acetate and buthanol, using a rotary evaporator in vacuum under reduced 
pressure at 40 °C, or by freezing and lyophilization of the water fraction. The dried weight of the single fractions 
compared to the quantity of the total extract was: 1) dichloromethane fraction, 22%; 2) ethyl acetate fraction, 3%; 
3) butanol fraction, 6%; 4) water fraction, 69%.
Animals. Male Sprague-Dawley (SD) rats (Harlan, Varese, Italy) weighing approximately 200 to 250 g at the 
beginning of the experimental procedure were used. Pirc (F344/NTac-Apcam1137) rats, originally obtained from 
Taconic (Taconic Farms, Inc. USA) were bred in CESAL (University of Florence, Italy) in accordance with the 
Commission for Animal Experimentation of the Italian Ministry of Health (Femia et al.44). Animals were housed 
in CeSAL (Centro Stabulazione Animali da Laboratorio, University of Florence) and used at least 1 week after 
their arrival.
Four rats were housed per cage (size 26 × 41 cm) kept at 23 ± 1 °C with a 12 h light/dark cycle, light at 7 a.m; 
were fed a standard laboratory diet and tap water ad libitum. All animal manipulations were carried out accord-
ing to the Directive 2010/63/EU of the European parliament and of the European Union council (22 September 
2010) on the protection of animals used for scientific purposes. The ethical policy of the University of Florence 
complies with the Guide for the Care and Use of Laboratory Animals of the US National Institutes of Health (NIH 
Publication No. 85-23, revised 1996; University of Florence assurance number: A5278-01). Formal approval to 
conduct the experiments described was obtained from the Animal Subjects Review Board of the University of 
Florence. Experiments involving animals have been reported according to ARRIVE guidelines51. All efforts were 
made to minimize animal suffering and to reduce the number of animals used.
Oxaliplatin model. SD rats were treated with 2.4 mg kg−1 oxaliplatin, administered i.p. for 5 consecutive 
days every week for 3 weeks (15 i.p. injections)52. Oxaliplatin was dissolved in 5% glucose solution.
The model used for the present research is consistent with the clinical practice. The dose of 2.4 mg kg−1 oxalip-
latin corresponds to the common human dosage (considering the Km factor 37 for the conversion of animal 
doses to the Human Equivalent Dose). The daily repeated administration of 2.4 mg kg−1 performed in the animal 
model provides a cumulative dose of 36 mg kg−1 corresponding to 1332 mg/m2. This dosage mimics the clinical 
cumulative oxaliplatin dose causing chronic neuropathy. The inorganic platinum plasmatic level on day 21 is 
3.573 ± 0.217 μ g/mL in our conditions, in line with human plasma concentrations53. Control animals received an 
equivalent volume of 5% glucose i.p. Behavioral and biochemical tests were performed on day 21. In the experi-
ment with Pirc rats, 9 female Pirc rats, aged 8 months were randomly allocated to oxaliplatin treatment (n = 4) or 
to the same treatment with 50%HA (n = 5). Oxaliplatin treatments of Pirc rats were set up considering the higher 
sensitivity to oxaliplatin toxicity of these animals in comparison to SD rats. The dose of 1.5 mg kg−1 was injected 
i.p. twice a week for 4 weeks till the full development of painful neuropathy.
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Extract treatments. The extracts, Aqu, 20%HA and 50%HA, were suspended in 1% carboxy methyl cel-
lulose (CMC) and administered p.o. every day for 3 weeks to SD rats. Aqu and 20%HA were administered at 
300 mg kg−1 whereas 50%HA was administered in a dose range of 30 to 300 mg kg−1. The fractions obtained 
from 50%HA were administered as follows: 1) dichloromethane fraction, 66 mg kg−1; 2) ethyl acetate fraction, 
9 mg kg−1; 3) butanol fraction, 18 mg kg−1; 4) water fraction, 207 mg kg−1. These doses were obtained consider-
ing the weight percent of the fractions (22%, 3%, 6% and 69% for fractions 1–4, respectively) compared to the 
quantity of the total extract and referred to the total extract dose of 300 mg kg−1. Extracts, or fractions, were orally 
administered every day for 3 weeks starting from the first day of oxaliplatin administration.
Pirc rats were treated with 300 mg kg−1 50%HA p.o. daily for 4 weeks starting from the first day of oxaliplatin 
administration. Behavioral evaluations were performed 24 h after the last injection when not otherwise specified.
Paw pressure test. The nociceptive threshold in the rat was determined by an analgesimeter (Ugo Basile, 
Varese, Italy) as previously described19 and reported in detail in the supplementary material (Supplementary 
Methods).
Von Frey test. An electronic Von Frey hair unit (Ugo Basile, Varese, Italy) was used according to a previously 
described method19 and reported in detail in the supplementary material (Supplementary Methods).
Cold plate test. The Cold plate apparatus was used according to a previously described method19. The tem-
perature of the cold plate was kept constant at 4 °C ± 1 °C. The method is reported in detail in the supplementary 
material (Supplementary Methods).
Sciatic nerves examination. On day 21, at the end of the last behavioral test session, SD rats belonging to 
each group were sacrificed under general anesthesia and ipsilateral sciatic nerves were fixed, dehydrated and infil-
trated with paraffin (Diapath, Milan, Italy). Sectioned tissues were evaluated immunohistochemically for p-NF-H 
as reported19. For details, see the supplementary material (Supplementary Methods).
L4-L5 DRG examination. SD rat lumbar dorsal root ganglia were subjected to the treatment described for 
the sciatic nerves, sectioned, and stained using the Azan-Mallory method as previously reported19. The ATF-3 
expression in L4-L5 DRGs was evidenced by the use of an anti-ATF-3 primary antisera (rabbit anti-ATF-3, 1:500; 
Santa Cruz Biotechnology), evidenced with diaminobenzidine as reported19. For details, see the supplementary 
material (Supplementary Methods).
Immunohistochemistry of spinal cord and brain glia. On day 21, SD rats were sacrificed, the L4/L5 
segments of the spinal cord were exposed from the lumbovertebral column via laminectomy and identified by 
tracing the dorsal roots from their respective DRG. The brains were removed, sliced in coronal sections and areas 
of interest were identified using Paxinos and Watson’s atlas (Paxinos and Watson, 1982). Quantification of the 
number and morphology of Iba1 immunoreactive microglia (rabbit, 1:1000; Wako Chemicals, Richmond, USA) 
and GFAP immunoreactive astrocytes (mouse, 1:5000; Chemicon, Temecula, USA) in the superficial dorsal horns 
of the spinal cord and in brain areas were performed in four cryostat sections (20 μ m) by a previously reported 
method19,21. For details see the supplementary material (Supplementary Methods).
mRNA level analysis. The sciatic nerve, L4-L5 DRGs and spinal cord of SD rats (day 21) were collected as 
described above. mRNA was extracted using TRI – Reagent© (Sigma Aldrich, Milan, Italy). cDNA was obtained 
using the iScript cDNA Synthesis Kit® (Bio Rad, Milan, Italy) according to the manufacturer’s protocol. Nrf2 
(Nuclear factor (erythroid-derived 2)-like 2) mRNA (GenBank accession number: NM_031789.2) was amplified 
using the following rat gene specific primers: forward: 5′ TGA CTC TGA CTC CGG CAT TTC 3′, reverse 5′ TCC 
ATT TCC GAG TCA CTG AAC 3′. NQO1 (NAD(P)H dehydrogenase, quinone 1) mRNA (GenBank accession 
number: NM_017000.3) was amplified using the following rat gene specific primers: forward: 5′ TCA TTT GGG 
CAA GTC CAT TCC 3′, reverse 5′ TGA GCA ATT CCC TCC TGC CCT 3′. 18 S ribosomal RNA (GenBank 
accession number: NR_046237.1) was considered as housekeeping gene and amplified using: forward: 5′ TAC 
CAC ATC CAA GGA AGG CAG CA 3′, reverse 5′ TGG AAT TAC CGC GGC TGC TGG CA 3′. Both sequences 
were amplified by GoTaq® Flexi DNA Polymerase 2,500 U (Promega, Milan, Italy). The amplicons were electro-
phoresed in 1.8% agarose gel containing ethidium bromide. The resultant bands were then quantified by densi-
tometry and the intensity of the signal normalized to18S, thus correcting for any possible uneven loading of RNA.
Liver and kidney histopathological examination. The liver and kidney (SD rats, day 21) were removed, 
cut into small pieces, and fixed in 10% neutral buffered formalin. After dehydration in gradual ethanol (50% to 
100%), they were cleared in xylene and embedded in paraffin. Sections (5 μ m thick) were stained with hematoxy-
lin and eosin dye and observed under a light microscope at an original magnification of 20X and 40X.
Determination of apoptosis in colon tumors and normal colon of Pirc rats. After the 4-week treat-
ments (described above), apoptosis was evaluated in paraffin-embedded sections (4 μ m thick) of normal colonic 
mucosa and tumors stained with hematoxylin-eosin, as reported54. At least 15 full longitudinal crypt sections of 
normal mucosa/rat were scored at the microscope, determining the presence of cells in each crypt with the fol-
lowing characteristics of apoptosis: cell shrinkage, loss of normal contact with the adjacent cells of the crypt, chro-
matin condensation or formation of round or oval nuclear fragments (“apoptotic bodies”). When clusters of more 
than one apoptotic body were seen within the diameter of one cell, these bodies were considered as fragments 
of one apoptotic cell. Tumor apoptosis was determined by scoring at least 500 cells/tumor for the presence of 
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apoptotic cells that were coded as described above. In tumors and colon mucosa, apoptosis was scored by a single 
observer on coded samples and quantified as apoptotic index (AI = number of apoptotic cells/cells scored  × 100).
Statistical analysis. Behavioral measurements were performed on 10 rats for each treatment carried out in 2 
different experimental sets. Results were expressed as means ± S.E.M. and the analysis of variance was performed 
by one-way ANOVA. A Bonferroni’s significant difference procedure was used as post-hoc comparison. One-way 
ANOVA followed by Bonferroni post-test were used for the mRNA level analysis of comparisons between groups. 
Histologic, morphometric, and immunohistochemical analyses were performed on 6 rats per group, evaluating 6 
sciatic nerves, 6 L4-L5 DRGs, and 6 spinal cord sections for each animal. DRG values are reported as means of L4 
and L5. One-way repeated-measures analysis of variance followed by the Student-Newman-Keuls post hoc test 
was used to compare the percentage of ATF-3-positive neurons in small, medium, and large neurons in L4-L5 
DRGs of oxaliplatin-treated rats. Histological studies of Pirc rats were analyzed by the t-test. For the rest of the 
comparisons, a Mann-Whitney test was used.
In all experimental procedures, the investigators were blind to the experimental status of each animal. In 
addition, all images were captured and analyzed by an investigator other than the one who took measurements 
to avoid possible bias. Data were analyzed using the “Origin 9” software (OriginLab, Northampton, MA). 
Differences were considered significant at a P < 0.05.
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